Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
ID: HT9402-26-Q-9101Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYAURORA, CO, 80011, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/workspace/contract/opp/f14c9c8aff0f480c9a04e16bad546109/view
Timeline
    Description

    The Department of Defense (DoD) is seeking quotations for pharmaceutical agents as part of the Pharmacy Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP) to support the Military Health System (MHS). This procurement aims to establish an effective pharmacy benefits program by evaluating the clinical and cost-effectiveness of various pharmaceutical agents, including oncological and antihemophilic agents, for inclusion in the DoD Uniform Formulary. Interested manufacturers must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025. For further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.

    Point(s) of Contact
    Tracy Banks
    tracy.e.banks2.civ@health.mil
    Stephanie Erpelding
    stephanie.j.erpelding.civ@health.mil
    Files
    Title
    Posted
    NDC Price List FAQ Class Review.pdf
    This document outlines instructions for filling out price appendices for government RFPs, specifically for Blanket Purchase Agreements (BPAs) and Average Dealer Price (ADP) submissions. For BPAs, vendors must complete yellow cells, which include package size and price per NDC, with the latter highlighting red if no quote is submitted for a condition set. The price per unit is auto-calculated. For ADP, vendors input non-FAMP and Federal Ceiling Prices, with a 0.0000% additional offered refund highlighting red if no quote is submitted. Total calculated refunds are auto-calculated. Both appendices provide tables for up to 10 NDCs; vendors needing more must contact the listed POCs. Formulary Notes in both sections offer insight into the P&T committee's decision-making process.
    NDC Price List-Antihemophilic Agents - Non-factor Agents.xlsx
    The Department of Defense (DOD) Uniform Formulary Class for ANTIHEMOPHILIC AGENTS, specifically NON-FACTOR AGENTS, is undergoing review by the P&T Committee from February 4-5, 2026. Quotes for this review are due by January 16, 2026. The document outlines various scenarios for formulary status (Uniform Formulary Before-Step, After-Step, and Non-Formulary After-Step) for Military Treatment Facility and Mail Order, indicating that "NO QUOTE" has been submitted for all listed NDC numbers across these scenarios. It also details the TRICARE Retail Refund scenarios for Tier 2 (Before-Step and After-Step) and Tier 3 (After-Step) agents, with similar indications of no quotes. Key notes include the potential for Prior Authorization (PA), special reimbursement methods, consideration of preferential status for non-generic agents (Tier 1), and possible exclusion from the TRICARE pharmacy benefit program. Step Therapy with a grandfathering process is outlined, requiring new patients to trial step-preferred agents. Manufacturers are reminded to submit fully executed signature pages with quote information, and the price per unit will be consistent across package sizes for a given dosage form and strength.
    NDC Price List-Oncological Agents - Myelofybrosis.xlsx
    The document outlines the Department of Defense (DOD) Uniform Formulary Class review for Oncological Agents, specifically for the Myelofibrosis subclass. It details the process for a Blanket Purchase Agreement (BPA) Appendix and an Additional Discount Program (ADP) Appendix. Key dates include a P&T Committee Meeting on February 4-5, 2026, and a quote due date of January 16, 2026. The document specifies various scenarios for drug inclusion in the Uniform Formulary (UF) and outlines conditions for both before-step and after-step therapy agents, as well as uniform and non-formulary options. It also introduces a step therapy addendum with grandfathering provisions and notes that prior authorization may apply. Manufacturers are instructed to submit fully executed signature pages with their quotes, and pricing for pharmaceutical agents will be consistent across all package sizes within a given dispensing venue. The ADP section details TRICARE Retail Refund scenarios for Tier 2 and Tier 3 drugs, including how total calculated refunds are derived based on Non-FAMP and Federal Ceiling Price.
    RFQ HT9402-26-Q-9101 CR.pdf
    The Department of Defense (DoD) Defense Health Agency (DHA) has issued a Request for Quotation (RFQ) for pharmaceutical agents to be included in the DoD Uniform Formulary (UF). This RFQ outlines the process for manufacturers to submit offers, including UF Blanket Purchase Agreements (BPA) for Military Treatment Facilities (MTF) and TRICARE Mail Order Pharmacy (TMOP), and UF Additional Discount Program (ADP) agreements for the TRICARE retail network. The DoD Pharmacy and Therapeutics (P&T) Committee will evaluate pharmaceutical agents based on clinical and cost-effectiveness to determine their placement on the UF and their cost-share tier classification (generic, formulary, or non-formulary). The RFQ details submission steps, general information, points of contact, key dates, and specific instructions for both BPA and ADP quotes, emphasizing compliance and pricing requirements. It also defines terms and acronyms relevant to the DoD's pharmacy benefits program.
    Similar Opportunities
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is soliciting quotes for pharmaceutical agents as part of its Uniform Formulary Blanket Purchase Agreement (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) through the Defense Health Agency (DHA). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs to determine their classification within the formulary. The P&T Committee will review newly approved drugs, including agents for pulmonary, gynecological, endocrine, atopy, skeletal muscle relaxants, and pain management, with quotes due by December 9, 2025, ahead of the committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Stephanie Erpelding or Tracy Banks for further details and ensure compliance with submission requirements outlined in the RFQ HT9402-26-Q-9102.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--Dimethyl Fumarate Capsules
    Buyer not available
    The Department of Veterans Affairs (VA) is seeking offers for the procurement of Dimethyl Fumarate Capsules (120MG and 240MG delayed-release) through solicitation 36E79726R0003. This contract aims to establish a reliable supply source for these pharmaceutical products to support VA, Department of Defense (DoD), Indian Health Service (IHS), and Bureau of Prisons (BOP) facilities, with a contract structure that includes a one-year base ordering period and four one-year options. The products are critical for treating specific medical conditions, and offerors must comply with stringent requirements, including FDA regulations, Drug Supply Chain Security Act (DSCSA) compliance, and the provision of unique National Drug Codes (NDCs). The deadline for submitting offers has been extended to December 9, 2025, at 2:30 PM CST, and interested parties can contact Contract Specialist Kenneth Lay at Kenneth.Lay@va.gov for further information.
    Rabeprazole Sodium Delayed Release Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Ondansetron Orally Disintegrating Tablets
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    Metformin HCL
    Buyer not available
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    65--PYRIDOSTIGMINE BROM
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is seeking quotes for the procurement of Pyridostigmine Bromide, specifically NSN 6505-01-725-2767, under a total small business set-aside. The requirement includes a quantity of 1,000 units to be delivered to the W05J Medical Maintenance Operations Division at Tobyhanna within 20 days after the order is placed. Pyridostigmine Bromide is a critical medication used to treat certain conditions, making this procurement essential for military medical operations. Interested vendors must submit their quotes electronically, and any inquiries should be directed to the buyer via email at DibbsBSM@dla.mil, as hard copies of the solicitation will not be provided.
    DLA MedSurg Prime Vendor Gen VI
    Buyer not available
    The Defense Logistics Agency (DLA) is seeking proposals for the Medical Surgical Prime Vendor (Med/Surg PV) Program, which aims to provide a comprehensive range of medical and surgical supplies across three Global Regions: North, South, and West. This procurement involves the establishment of Firm Fixed-Price Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for both Primary and Backup Prime Vendors, with a focus on delivering commercially available off-the-shelf medical supplies to various military and federal healthcare facilities. The selected vendors will play a crucial role in ensuring the readiness and availability of essential medical products, supporting the operational needs of the Army, Air Force, Navy, Marine Corps, and other federal agencies. Interested offerors must submit their proposals electronically via the DLA Internet Bid Board System (DIBBS) by December 10, 2025, at 3:00 PM Local Philadelphia Time, and are encouraged to attend a virtual pre-proposal conference scheduled for October 22, 2025. For further inquiries, contact Beatrice Lopez-Pollard at beatrice.lopez-pollard@dla.mil or Joshua Tankel at Joshua.Tankel@dla.mil.
    Atropine and Pralidoxime Chloride, 'Duodote Kit"
    Buyer not available
    The Department of Health and Human Services, specifically the Office of the Assistant Secretary for Administration, is seeking quotes for the procurement of Atropine and Pralidoxime Chloride Autoinjectors, known as the "Duodote Kit." The requirement includes a total of 171 boxes, each containing 30 autoinjectors, to be delivered to the DHHS Receiving Dock located in Perry Point, Maryland. These autoinjectors are critical for emergency medical treatment, particularly in cases of organophosphate poisoning. Interested vendors should direct their inquiries to Tim Bouchelle at Timothy.Bouchelle@hhs.gov or by phone at 443-947-6039, with no set-aside restrictions applicable to this solicitation.